The availability of the K-RasG12D-based models of ROS1-positive NSCLC, described herein, will allow us to test whether adding ROS1 targeting to this combined treatment would result in an even more effective anti-tumor strategy—one that could ensure the long-lasting and specific activation of the cellular immune response. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.